tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Sarepta Therapeutics Inc

SRPT
Add to Watchlist
19.380USD
-1.430-6.87%
Market hours 09/23, 11:27（ET）
2.05BMarket Cap
31.10P/E TTM

Sarepta Therapeutics Inc

19.380
-1.430-6.87%
Overview
News&Analysis
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

News&Analysis

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

SRPT Financials

See Sarepta Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
2.05B
Dividend TTM
0.00
P/E TTM
31.10
EPS TTM
0.62
Revenue
2.20B
Net Profit
235.24M
ROE
4.91%
ROA
1.96%

Sarepta Therapeutics Inc Earnings Date

Latest Release
Aug 5, 2026
EPS / Forecast
-0.05/0.26
Revenue / Forecast
401.25M/364.34M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
-102.31%-0.05
168.58%3.15
-263.33%-2.70
-609.50%-1.80
2842.73%2.01
-1296.09%-4.60
275.41%1.65
176.51%0.35
125.31%0.07
106.56%0.38
135.38%0.44
---0.46
---0.27
---5.86
---1.24
---6.79
----
----
----
----
Revenue
-34.34%401.25M
-1.89%730.80M
-32.73%442.93M
-14.52%399.36M
68.38%611.09M
80.15%744.86M
65.94%658.41M
40.79%467.17M
38.93%362.93M
63.10%413.46M
53.54%396.78M
44.10%331.82M
11.89%261.24M
20.24%253.50M
28.28%258.43M
21.57%230.27M
42.29%233.49M
43.49%210.83M
38.81%201.46M
31.60%189.41M
Net Profit
-102.48%-4.89M
173.96%330.96M
-277.84%-282.85M
-635.38%-179.95M
2947.86%196.89M
-1338.98%-447.51M
248.37%159.05M
182.10%33.61M
126.98%6.46M
106.99%36.12M
141.79%45.66M
84.12%-40.94M
89.66%-23.94M
-392.03%-516.75M
10.44%-109.24M
-435.35%-257.74M
-184.36%-231.48M
37.20%-105.03M
35.57%-121.98M
75.50%-48.14M
Net Margin
-103.78%-1.22%
175.38%45.29%
-364.35%-63.86%
-726.30%-45.06%
1710.15%32.22%
-787.75%-60.08%
109.94%24.16%
158.32%7.19%
119.42%1.78%
104.29%8.74%
127.22%11.51%
---12.34%
---9.16%
---203.85%
---42.27%
---88.09%
----
----
----
----
Gross Margin
-16.46%62.59%
4.38%85.02%
-40.92%47.15%
-22.64%62.08%
-14.43%74.93%
-7.05%81.45%
-9.99%79.81%
-9.54%80.24%
0.80%87.56%
1.75%87.63%
0.75%88.67%
--88.71%
--86.87%
--86.12%
--88.01%
--83.73%
----
----
----
----
Debt to assets ratio
-14.15%26.58%
-19.73%26.37%
-13.75%24.75%
-13.10%29.63%
-13.54%30.97%
-14.53%32.85%
-24.34%28.69%
-14.26%34.10%
-9.39%35.81%
-4.72%38.43%
-23.18%37.92%
--39.77%
--39.53%
--40.34%
--49.36%
--48.88%
----
----
----
----
Income Statement
Revenue
-34.34%401.25M
-1.89%730.80M
-32.73%442.93M
-14.52%399.36M
68.38%611.09M
80.15%744.86M
65.94%658.41M
40.79%467.17M
38.93%362.93M
63.10%413.46M
53.54%396.78M
44.10%331.82M
11.89%261.24M
20.24%253.50M
28.28%258.43M
21.57%230.27M
42.29%233.49M
43.49%210.83M
38.81%201.46M
31.60%189.41M
Operating profit
-54.76%52.29M
219.32%358.43M
-251.40%-244.78M
-383.29%-62.88M
16587.45%115.58M
-960.58%-300.39M
556.57%161.68M
206.50%22.20M
99.47%-701.00K
125.28%34.91M
123.05%24.63M
84.13%-20.84M
36.76%-133.52M
-58.94%-138.09M
-0.96%-106.83M
-281.20%-131.35M
-25.99%-211.13M
38.76%-86.88M
38.02%-105.81M
74.86%-34.46M
Net Profit
-102.48%-4.89M
173.96%330.96M
-277.84%-282.85M
-635.38%-179.95M
2947.86%196.89M
-1338.98%-447.51M
248.37%159.05M
182.10%33.61M
126.98%6.46M
106.99%36.12M
141.79%45.66M
84.12%-40.94M
89.66%-23.94M
-392.03%-516.75M
10.44%-109.24M
-435.35%-257.74M
-184.36%-231.48M
37.20%-105.03M
35.57%-121.98M
75.50%-48.14M
Balance Sheet
Current assets
-16.30%2.22B
-5.04%2.31B
-17.42%2.54B
1.38%2.72B
-0.99%2.66B
-1.31%2.43B
19.16%3.07B
9.57%2.69B
8.53%2.68B
-0.94%2.46B
0.84%2.58B
-6.67%2.45B
0.13%2.47B
-1.68%2.49B
-1.78%2.56B
20.16%2.63B
9.01%2.47B
11.43%2.53B
4.78%2.60B
-5.91%2.19B
Total current liabilities
-45.33%502.91M
-17.57%499.16M
49.69%1.10B
31.73%921.42M
33.62%919.95M
-0.51%605.59M
11.94%731.68M
55.19%699.49M
38.07%688.49M
13.38%608.71M
5.50%653.66M
-25.24%450.74M
-8.60%498.65M
18.01%536.88M
36.86%619.60M
61.45%602.92M
28.36%545.57M
24.74%454.96M
8.82%452.73M
-1.31%373.44M
Total assets
-13.35%3.19B
-8.27%3.18B
-15.48%3.35B
-2.96%3.49B
7.46%3.68B
7.47%3.47B
21.40%3.96B
15.76%3.60B
9.55%3.42B
5.38%3.22B
4.35%3.26B
-1.47%3.11B
4.31%3.13B
0.12%3.06B
-0.62%3.13B
18.55%3.16B
8.62%3.00B
10.52%3.06B
5.47%3.15B
-4.26%2.66B
Total liabilities
-28.49%1.66B
-27.93%1.67B
-9.29%2.21B
-8.64%2.17B
-1.05%2.32B
2.63%2.32B
1.26%2.44B
1.43%2.38B
-1.56%2.35B
-3.57%2.26B
-12.33%2.41B
-13.94%2.35B
5.02%2.38B
6.72%2.35B
23.58%2.74B
24.29%2.73B
-0.16%2.27B
-1.37%2.20B
-0.13%2.22B
16.10%2.19B
Total equity
12.55%1.53B
31.71%1.51B
-25.34%1.14B
8.11%1.32B
26.03%1.36B
18.89%1.14B
77.78%1.53B
59.75%1.22B
45.27%1.08B
34.86%961.19M
123.23%859.34M
77.41%764.36M
2.06%741.41M
-16.82%712.75M
-58.52%384.95M
-8.24%430.84M
49.75%726.46M
60.03%856.89M
21.82%928.01M
-47.37%469.53M
Cash Flow Statement
Net operating income
-24.59%197.07M
65.26%-202.68M
42.54%131.21M
79.37%-14.59M
1649.01%261.34M
-141.01%-583.44M
268.41%92.05M
38.37%-70.70M
112.22%14.94M
-15.61%-242.08M
40.84%-54.66M
-76.57%-114.71M
-82.94%-122.23M
-106.96%-209.40M
-215.05%-92.39M
47.75%-64.96M
38.78%-66.81M
43.91%-101.17M
83.20%-29.33M
47.80%-124.33M
Net investment
-389.88%-93.37M
53.85%-134.39M
-87.41%96.21M
280.40%232.40M
132.69%32.21M
-233.08%-291.18M
1287.29%764.12M
38.82%-128.82M
-201.96%-98.53M
1651.49%218.80M
-756.98%-64.36M
-1201.37%-210.57M
133.32%96.63M
101.59%12.49M
480.13%9.80M
-5.66%19.12M
-190.32%-289.99M
-601.58%-785.81M
97.92%-2.58M
-62.52%20.27M
Net financing
100.00%0.00
-98.07%241.00K
-180.03%-39.21M
-956.22%-117.79M
-159.66%-23.82M
-43.67%12.47M
2421.41%48.99M
-10.70%13.76M
581.08%39.92M
-78.25%22.14M
-81.92%1.94M
-92.88%15.40M
1628.91%5.86M
1939.98%101.80M
-98.04%10.75M
3567.05%216.43M
-90.39%339.00K
72.49%4.99M
68.00%549.25M
-68.59%5.90M

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its total revenue reached 2.20B, with a year-on-year change of 1.90B.

What are the current assets of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its current assets were 2.54B, with a year-on-year change of -17.42.

What are the total assets of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its total assets of Sarepta Therapeutics Inc were 3.35B, with a year-on-year change of -15.48.

What are the total liabilities of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its total liabilities of Sarepta Therapeutics Inc were 2.21B, with a year-on-year change of -9.29.

What is the total equity of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its total equity of Sarepta Therapeutics Inc was 1.14B, with a year-on-year change of -25.34.

What is the net operating income of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its net operating income of Sarepta Therapeutics Inc was -492.47M, with a year-on-year change of -325.82.

What is the net investment of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its net investment of Sarepta Therapeutics Inc was 69.64M, with a year-on-year change of -90.78.

What is the net financing of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its net financing of Sarepta Therapeutics Inc was -168.34M, with a year-on-year change of -234.88.

What is the Earnings Per Share (EPS) of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -7.13, with a year-on-year change of -387.99.

What is the net income of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its net income was -713.41M, with a year-on-year change of -403.27.

What is the net margin of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its net profit margin was -32.45, with a year-on-year change of -362.40.

What is the gross margin of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its gross margin was 69.21, with a year-on-year change of -16.72.

What is the debt-to-asset ratio of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its debt-to-asset ratio was 24.75, with a year-on-year change of -13.75.

What is the Return on Equity (ROE) of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -53.47, with a year-on-year change of -371.30.

What is the Return on Assets (ROA) of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -19.51, with a year-on-year change of -399.74.

What is the operating profit of Sarepta Therapeutics Inc?

According to Sarepta Therapeutics Inc's FY2025 earnings report, its operating profit was -492.47M, with a year-on-year change of -325.82.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy